The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care.
 
Tiffany A. Traina
Consulting or Advisory Role - Aduro Biotech; Advaxis; AstraZeneca; Athenex; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genomic Health; Halozyme; Immunomedics; Innocrin Pharma; Ionis Pharmaceuticals; Merck; Pfizer; Puma Biotechnology; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Carrick Pharm (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Philip W. Kantoff
Leadership - Context Therapeutics
Stock and Other Ownership Interests - Context Therapeutics; Druggablity Technologies; Placon; Seer
Consulting or Advisory Role - Bavarian Nordic; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; Seer; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
 
Matthew J. Matasar
Stock and Other Ownership Interests - Merck
Honoraria - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Seagen; Takeda
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Takeda; Teva
Research Funding - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen
 
Lara Dunn
Consulting or Advisory Role - CUE Biopharma; CUE Biopharma; Regeneron
Research Funding - Eisai; Pfizer; Regeneron
 
Claire Frances Friedman
Honoraria - Aptitude Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - Seagen
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech; Merck
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - AVEO; Calithera Biosciences; Corvus Pharmaceuticals; Eisai; Exelixis; Merck; Pfizer
Research Funding - Pfizer
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
Other Relationship - BMS
 
Andrew David Seidman
Honoraria - AstraZeneca; Eisai; Genentech/Roche; Genomic Health; Immunomedics; Lilly; Novartis
Consulting or Advisory Role - BeyondSpring Pharmaceuticals; Eisai; Genentech/Roche; Immunomedics; Lilly; Novartis; Odonate Therapeutics; Pfizer
Speakers' Bureau - AstraZeneca/MedImmune; Eisai; Genentech/Roche; Genentech/Roche; Genomic Health; Lilly; Novartis/Pfizer
Research Funding - Bayer; Nektar (Inst); Odonate Therapeutics (Inst)
 
Oren Cahlon
No Relationships to Disclose
 
Marjorie Glass Zauderer
Honoraria - Medical Learning Institute
Consulting or Advisory Role - Aldeyra Therapeutics; Atara Biotherapeutics; GlaxoSmithKline; Novocure; Takeda
Research Funding - Atara Biotherapeutics (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Polaris (Inst); Sellas Life Sciences (Inst)
(OPTIONAL) Uncompensated Relationships - Mesothelioma Applied Research Foundation
 
Cole Manship
No Relationships to Disclose
 
Emily Kauff
No Relationships to Disclose
 
Gitika Srivastava
Stock and Other Ownership Interests - Navya Network Inc
 
Naresh Ramarajan
Stock and Other Ownership Interests - Navya Network Inc
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris